Scientist Solutions: International Life Science Community By Scientists For Scientists
    
Home » Protocols » PTM-Ab™ technology for Post-translational Modification Specific Antibody Discovery
Thanks to our sponsors who make this site possible
Protocol for

PTM-Ab™ technology for Post-translational Modification Specific Antibody Discovery

Would you like to save this topic, event, protocol or job so you can find it again easily?

Just click the "Save to My Lab Drawer" link and the item will be saved in the My Lab Drawer section of your bench space.

Available to members only. Please log in or register for your free account now.

Abstract or Description:

 Many cellular activities are controlled by post-translational modifications, the study of which is hampered by the lack of specific reagents due in large part to their ubiquitous and non-immunogenic nature. Creative Biolabs has developed PTM-Ab™ technology, which offers antibody discovery services that specific for post-translational modifications on proteins.

Post-translational modifications are modifications that occur on a protein, catalysed by enzymes, after its translation by ribosomes is complete. Post-translational modification generally refers to the addition of a functional group covalently to a protein as in phosphorylation and neddylation. Protein post-translational modifications play a key role in many cellular processes such as cellular differentiation, protein degradation, signaling and regulatory processes, regulation of gene expression, and protein-protein interactions. These modifications influence almost all aspects of normal cell biology and pathogenesis. Therefore, identifying and understanding PTMs is critical in the study of cell biology and disease treatment and prevention.
 

PTM-Ab™ provides antibody discovery on post-translational modifications of:

Phosphorylation  •Sumoylation
• Acetylation  • Alkylation
Glycosylation  • ISGylation
Methylation • Neddylation
• Ubiquitination • Pupylation

Creative Biolabs employs phage display technology to support our post-translational modification specific antibody discovery.

Phage display platform for post-translational modification specific antibody discovery

Our staff scientists have extensive experience in screening of phage display peptide, cDNA and scFv/Fab libraries. In particular, by conducting library screening, panning, for 4 cycles, we normally get scFv/Fab antibodies of an affinity of 
10-10 M.

In comparison with hybridoma technology, phage display antibody library technology offers great advantages. Hybridoma based monoclonal antibody technology can only generate a small number of binders against a particular immunogen at a time; whereas phage display technology can present the entire antibody repertoire [e.g., 10*10] of an immunized animal, in which almost 10% of the antibodies are immunogen[s]-specific. With such a huge pool of potential binders, the chance is much better to use phage display technology to discover posttranslational modification specific antibodies. In addition, using hybridoma technology, it is hard to incorporate an enriching step that can selectively isolate antibodies of desired functionality. In most cases, all the hybridoma clones are produced first and then validated one by one. In contrast, phage display technology allows various enriching strategies: posttranslational modification specific antibodies can be enriched thus those without the desired functionality can be excluded from further validation. For example, antibody library screening can be done using the PTM-modified target to capture strong binders while using the unmodified controls to block/deplete cross-reactive binders. In particular, biopanning allows isolation of antibodies of the strongest affinity from the immunized animals.

Citation:
Attachments: No Attachments
Posted By: Candy Ton on 5/18/2015 3:20:41 PM
Comments
Add Comment